The U.S. Food and Drug Administration said on Monday that it had launched a generative AI tool, Elsa, aimed at improving efficiency across its operations, including scientific reviews.
“Today’s rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers,” said FDA Commissioner Marty Makary.
The agency said it is already using Elsa to expedite clinical protocol reviews, shorten the time needed for scientific evaluations, and pinpoint high-priority inspection targets.
Once the FDA receives an application for a potential drug approval, it has six to 10 months to make a decision.
Elsa assists with reading, writing, and summarizing tasks. It can summarize adverse events to support safety profile assessments of drugs and rapidly compare packaging inserts.
“Elsa offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency. The models do not train on data submitted by regulated industry, safeguarding the sensitive research and data handled by FDA staff,” the FDA said.
In May, the regulator said it would fully integrate AI by June 30, following an experimental run.
—Puyaan Singh, Reuters
Autentifică-te pentru a adăuga comentarii
Alte posturi din acest grup
Did you wake up at 4 a.m. on November 6, 2024? If so, you’re not alone.
The 4 a.m. club is a group of people, mostly on TikTok, who say they were spiritually “activated” when they
New analysis has found mobile phone users are being pinged with as many as 50 news alerts daily. Unsurprisingly, many are experiencing “alert fatigue.”
The use of news alerts on phones h
The startup Warp is best known for its modern, AI-empowered take on the terminal—the decades-old,
Want to save pages on the web for later? You could always bookmark them in your browser of choice, of course. But that’s a quick way to end up with a messy bookmarks toolbar. And organizing your b
When a viral Reddit post revealed that ChatGPT cured a five-year medical mystery in seconds, even LinkedIn’s Reid Hoffman took notice. Now, OpenAI’s Sam Altman says Gen Z and Millennials are treat
Everyone who’s ever talked to ChatGPT, Claude, Gemini, and other big-name chatbots recognizes how anodyne they can be. Because these conversational AIs’ creators stuff them with as much human-gene
